InDex Pharmaceuticals   Report issue

For profit Phase 3
Founded: Stockholm Sweden (2000)

Organization Overview

First Clinical Trial
2011
NCT01493960
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

InDex Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (1)

cobitolimod (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1